Evaluation of US20150011555. An inhaled IP receptor agonist for the treatment of pulmonary arterial hypertension

Bibliography

• McGoon MD, Benza RL, Escribano-Subias P, et al. pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013;62(25 Suppl):D51-9
   PubMed Web of Science ®Google Scholar
• Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D13-21
   PubMed Web of Science ®Google Scholar
• Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med 2010;104(4):481-96
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D42-50
   PubMed Web of Science ®Google Scholar
• Galiè N, Hoeper MM, Humbert H, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493-537
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119:2250-94
   PubMed Web of Science ®Google Scholar
• Baldi F, Fuso L, Arrighi E, Valente S. Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course. Ther Clin Risk Manag 2014;10:825-39
   PubMed Web of Science ®Google Scholar
• Borchert J, Franke J, Lichey J. Reduction of acute pulmonary hypertension by prostacyclin. Cor Vasa 1980;22(4):281-7
   PubMed Web of Science ®Google Scholar
• Chin KM, Badesch DB, Robbins IM, et al. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. Am Heart J 2014;167(2):218-225.e1
   PubMed Web of Science ®Google Scholar
• Buckley MS, Feldman JP. Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults. Pharmacotherapy 2010;30(7):728-40
   PubMed Web of Science ®Google Scholar
• Melian EB, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 2002;62(1):107-33
   PubMed Web of Science ®Google Scholar
• Sakao S, Tanabe N, Kasahara Y, Tatsumi K. Long-term survival of Japanese patients with pulmonary arterial hypertension treated with beraprost sodium, an oral prostacyclin analogue. Intern Med 2014;53(17):1913-20
   PubMed Web of Science ®Google Scholar
• Scott JP, Higenbottam T, Wallwork J. The acute effect of the synthetic prostacyclin analogue iloprost in primary pulmonary hypertension. Br J Clin Pract 1990;44(6):231-4
   PubMedGoogle Scholar
• John J, Palevsky H. Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension. Expert Rev Clin Pharmacol 2011;4(2):197-205
   PubMedGoogle Scholar
• McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analogue for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003;41(3):293-9
   PubMedGoogle Scholar
• Channick RN, Voswinckel R, Rubin LJ. Inhaled treprostinil: a therapeutic review. Drug Des Devel Ther 2012;6:19-28
   PubMed Web of Science ®Google Scholar
• Torres F, Rubin LJ. Treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Cardiovasc Ther 2013;11(1):13-25
   PubMedGoogle Scholar
• Buckley MS, Berry AJ, Kazem NH, et al. Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review. Core Evid 2014;9:71-80
   PubMedGoogle Scholar
• Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):56S-61S
   PubMed Web of Science ®Google Scholar
• Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012;40(4):874-80
   PubMed Web of Science ®Google Scholar
• Skoro-Sajer N, Lang IM. Selexipag for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2014;15(3):429-36
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hashino A, Noda K, et al. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther 2008;326(3):691-9
   PubMed Web of Science ®Google Scholar
• Tran TA, Shin YJ, Kramer B, et al. Discovery of a new series of potent prostacyclin receptor agonists with in vivo activity in rat. Bioorg Med Chem Lett 2015;25(5):1030-5
   PubMed Web of Science ®Google Scholar
• Semple G. Discovery of APD811: an orally available prostacyclin receptor agonist for the treatment of Pulmonary Arterial Hypertension (PAH). 4th RSC/SCI GPCRs in Medicinal Chemistry; 17–19 September 2012; Surrey, UK
   Google Scholar
• Novartis AG. Salts of an IP receptor agonist. US20150011555; 2015
   Google Scholar
• Novartis AG. IP receptor agonist heterocyclic compounds. WO2012007539; 2012
   Google Scholar
• LeBlanc C. The discovery of the first, designed for inhalation, prostacyclin receptor agonist for pulmonary arterial hypertension. 18th SCI/RSC Medicinal Chemistry Symposium; 13–16th September 2015; Cambridge
   Google Scholar
• Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013;127(10):1128-38
   PubMed Web of Science ®Google Scholar
• Norman P. Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension. Expert Opin Ther Pat 2015;25(4):493-9
   PubMed Web of Science ®Google Scholar